LONG TERM PHYSICO-CHEMICAL STABILITY OF IPILIMUMAB IN OPENED COMMERCIAL VIAL

Pascale BARDO, Victoire VIEILLARD, Alain ASTIER, Muriel PAUL Pharmacy Department, Henri Mondor Hospital, AP-HP, Créteil, France





Ipilimumab (IPI) is a human monoclonal antibody indicated in the treatment of metastatic melanoma. This expensive medecine is generally prepared in cytotoxic preparation Pharmacy units. The stability is a major matter for pharmacist, and in this case, the manufacturer indicates a stability of only 24 hours after vial opening.

MATERIAL AND METHOD / OBJECTIVE

Physical stability analysis:

- UV spectroscopy 350 nm: turbidity
- Dynamic Light Scattering (DLS)
- Thermal denaturation curve
- Size Exclusion Chromatography (SEC)

Chemical stability analysis:

- Ionic Exchange Chromatography (IEC)
- UV second derivative








Practical conditions study

- 2 glasses : one stored at each temperature :
 - 4°C: traditional keeping conditions
 - 25°C: in case of out of the cold chain
- Ready to use solution in commercial vial (5 mg/mL)
- In light-protecting bags
- Samples withdrawn in aseptic conditions
- Times of analysis:: T0 (control), 2 weeks, M1, M2 and M3



Objective


Study the physico-chemical stability of IPI in open commercial glass vial at 25°C and 4°C during 3 months

Expected answers:

→Use of vial residues? → Maintained stability after air inlet or metal ions?


Results are presented as median +/- standard deviation (T0 versus 3 months) and measures were repeated 3 times. Statistical analysis was performed by non-parametric Wilcoxon tests (significance = p < 0.05).

RESULTS AND DISCUSSION



No significant modification of **turbidity** was observed at 350 nm, unlike after heating.

60°C Heating	Mean OD at 350 nm
T0 not heated	0,0854 +/- 0,0009
T 8h heated	0,2477 +/- 0,0047
T 48h heated	0,3019 +/- 0,0054




Size Distribution by Intensity


- No significant modification of mean hydrodynamic diameters mesured by DLS
- Low polydispersity index (< 0,1)
- → Monodisperse population

Mean diameter in DLS (nm)	ТО	M3
4°C vial	12,04 +/- 0,07	11,82 +/- 0,06
25°C vial	11,94 +/- 0,26	11,94 +/- 0,26

We observed the pre-existence of High Weigh Particules (HWP) as dimers or tetramers in the commercial solution and a major peak which is the monomer.



The chromatographic profile in **SEC** was not modified up to 3 months:




- 3 months SEC profiles were stackable to T0 at each temperature
- No chain scission was observed

	4°C vial		25°C vial		60 C heated solution	
	ТО	M3	ТО	M3	ТО	H 96
% HWP	4,45	4,89	4,06	5,14	5,26	7,21
% Dimer	10,61	11,47	10,51	13,14	14,67	18,99
% Monomer	84,94	83,64	85,43	81,72	80,06	73,8

Temperature of aggregation (Tm) stayed around 73,4°C

			A (10° a.nm)
Mean Tm (°C)	ТО	M3	4
4°C vial	73,4°C	73,3°C	3. 2.566
25°C vial	73,3°C	73,4°C	2.
			1 60 65 70 75 80 T


- derivatives second were stackable to control T0:
- -at both temperatures
- -at each analysis times
- → No change in tertiary structure



Ionic chromatography (IEC):

- chromatogram month profile was not modified -none new peak appeared
- = no chemical instability

→ No desamidation



IEC was not performed at M3 for technical reasons: we will perform it again.

News methods will be needed to confirm these results:

- -Peptide mapping: primary structure
- -IR spectroscopy: secondary structure
- -Biological activity



Physical stability seemed to be maintained according to unchanged:

- turbidity -> absence of aggregation
- hydrodynamic diameters
- Tm and SEC profiles.

And chemically stability was ascertained by:

- no chain scission in SEC
- no desamidation in IEC
- and UV second derivatives remained similar -> absence of tertiary structure modification.

CONCLUSION

We demonstrated that Ipilimumab stored in original vials at 4 and 25°C remained stable up to 3 months. No significant physical or chemical instability was observed. Extended stability of unused vial residues, for a very expensive product like IPI, could permit an important cost saving in hospitals.